key: cord-0881785-ez30o1w2
authors: Rosas Mejia, Oscar; Gloag, Erin S.; Li, Jianying; Ruane-Foster, Marisa; Claeys, Tiffany A.; Farkas, Daniela; Wang, Shu-Hua; Farkas, Laszlo; Xin, Gang; Robinson, Richard T.
title: Mice infected with Mycobacterium tuberculosis are resistant to acute disease caused by secondary infection with SARS-CoV-2
date: 2022-03-24
journal: PLoS Pathog
DOI: 10.1371/journal.ppat.1010093
sha: 5f073c7fa09865f013466ed0e243d393fce299ba
doc_id: 881785
cord_uid: ez30o1w2

Mycobacterium tuberculosis (Mtb) and SARS-CoV-2 (CoV2) are the leading causes of death due to infectious disease. Although Mtb and CoV2 both cause serious and sometimes fatal respiratory infections, the effect of Mtb infection and its associated immune response on secondary infection with CoV2 is unknown. To address this question we applied two mouse models of COVID19, using mice which were chronically infected with Mtb. In both model systems, Mtb-infected mice were resistant to the pathological consequences of secondary CoV2 infection, and CoV2 infection did not affect Mtb burdens. Single cell RNA sequencing of coinfected and monoinfected lungs demonstrated the resistance of Mtb-infected mice is associated with expansion of T and B cell subsets upon viral challenge. Collectively, these data demonstrate that Mtb infection conditions the lung environment in a manner that is not conducive to CoV2 survival.

The world is currently in the midst of two lung disease pandemics: COVID19 and tuberculosis (TB), the causative agents of which are SARS-CoV-2 (CoV2) and Mycobacterium tuberculosis (Mtb), respectively. Although COVID19 

Mycobacterium tuberculosis and SARS-CoV-2 coinfection in mice This pattern, wherein Mtb monoinfection induces high levels of a gene expression that are unchanged upon CoV2 challenge, was also observed for IFNγ and TNFα at the mRNA level (Fig 2D and 2E) ; however and notably, the resistance of Mtb POS CoV2 POS mice did not associate with elevated expression of the antiviral genes IFIT2 and IFIT3, which are otherwise induced in Mtb NEG CoV2 POS mice (Fig 2F and 2G) , nor was CoV2 able to induce CCL2 expression in the presence of Mtb (Fig 2H) . Expression of the anti-inflammatory cytokine IL10 was low in all experimental groups relative to UI controls (Fig 2I) . At a histological level, the lungs of Mtb NEG CoV2 POS mice exhibited a number of previously reported features [14] by post-challenge Day 4 (Fig 3A) and Day 7 (Fig 3B) , including diffuse alveolar damage with inflammatory infiltrates and alveolar necrosis. Since these features were also observed in granulomatous lesions of Mtb POS CoV2 NEG lungs, a hallmark of Mtb infection, On the indicated days, lung tissue from Mtb NEG CoV2 POS , Mtb POS CoV2 NEG , Mtb POS CoV2 POS and uninfected (UI) ACE2 mice was used to measure (A-C) protein levels of (A) IFNγ, (B) IL6 and (C) IL1β, as well as (D-I) mRNA levels of (D) IFNγ, (E) TNFα, (F) IFIT2, (G) IFIT3, (H) CCL2 and (I) IL10. This experiment was repeated twice, each with similar results (4 mice/ group/timepoint). � , p � 0.05 as determined by either Student's t-test or ANOVA; §, significant relative to UI protein levels.

https://doi.org/10.1371/journal.ppat.1010093.g002 

Mycobacterium tuberculosis and SARS-CoV-2 coinfection in mice we could not use histology to observe whether Mtb inhibits CoV2-induced inflammation and alveolar necrosis. What could be observed, however, were differences between Mtb NEG CoV2-POS and Mtb POS CoV2 POS lungs with regards to hyaline membrane formation and pneumonia in the terminal bronchioles by Day 7 (Fig 3B inset) , which were notable in Mtb NEG CoV2 POS lungs but absent from Mtb POS CoV2 POS lungs (pneumonia is not typical of Mtb-infected mice on the B6 background until~1 year after infection [15] ). The sizes of each individual TB granuloma in Mtb POS CoV2 NEG and Mtb POS CoV2 POS mice were similar at all time points (Fig 3C) , as were the cumulative lung area taken by all TB granulomas (Fig 3D) . Consistent with our assessment of lung CoV2 burdens (Fig 1C and 1D) , anti-N protein immunohistochemistry (IHC) staining demonstrated fewer and less intense IHC+ regions within Mtb POS CoV2 POS lungs, relative to Mtb NEG CoV2 POS lungs (Fig 3E and 3F) . Notably, the few IHC+ regions which were observed in Mtb POS CoV2 POS lungs were distal to granulomatous lesions that contain Mtb (Fig 3E) .

To determine whether Mtb-induced resistance to CoV2 was specific to the ACE2 transgenic model of COVID19, we performed the same set of experiments using a second mouse model of COVID19: MACoV2 infection of B6 mice [13] . As before, our experimental groups included B6 mice which were uninfected prior to MACoV2 challenge (Mtb NEG MACoV2 POS ), or Mtb-infected 30 days prior to challenge with MACoV2 (Mtb POS MACoV2 POS ) or vehicle control (Mtb POS MACoV2 NEG ) (Fig 4A) . Whereas ACE2 mice which lost �20% body weight within 7 days of CoV2 challenge (Fig 1B) , MACoV2 induced weight loss was less dramatic, with Mtb NEG MACoV2 POS mice losing �10% body weight within 7 days of MACoV2 challenge (Fig 4B) . Nevertheless and consistent with our ACE2 model results, Mtb POS MACoV2 POS were resistant to MACoV2-elicited weight loss (Fig 4B) , had lower viral burdens compared to Mtb NEG MACoV2 POS mice (Fig 4C and 4D ) and no change in lung Mtb burdens following virus challenge (Fig 4E) . Following virus challenge, Mtb NEG MACoV2 POS lungs exhibited transient increases in protein and mRNA levels of IFNγ (Fig 4F and 4G) , IL6 (Fig 4H) , IFIT3 (Fig  4I) , IFITM3 (Fig 4J) and ACE2 (Fig 4K) , consistent with previous reports of CoV2 inducing expression of its own receptor [16] . As was also observed in the ACE2 model (Fig 2A and 2B) , protein levels of IFNγ and IL6 were already high in Mtb POS MACoV2 NEG lungs and unaffected by MACoV2 challenge (Fig 4F and 4H ). MACoV2 elicited IFIT3 expression in both Mtb NEG-MACoV2 POS and Mtb POS MACoV2 POS lungs, albeit lower in the latter group (Fig 4J) . The resistance of Mtb-infected B6 mice to CoV2 was not attributable to an absence of lung ACE2 expression, as Mtb POS MACoV2 POS mice expressed higher than UI levels of ACE2 ( Fig 4K) ; unlike Mtb NEG MACoV2 POS mice, however, ACE2 expression in Mtb POS MACoV2 POS lungs was not affected by MACoV2 challenge (Fig 4K) .

Finally, to discern the lung immune environment associated with MACoV2 resistance in Mtb-infected mice, we used scRNA-seq to analyze live CD45+ cells from the lungs of each group (UI, Mtb NEG MACoV2 POS , Mtb POS MACoV2 NEG and Mtb POS MACoV2 POS ) on postchallenge Day 7. This timepoint enabled us to analyze immune cells after PFU are no longer detectable (Fig 4C) . Live CD45+ cells were purified from the lungs of each group (4 mice per group) and used to prepare single-cell transcriptome datasets. These datasets separated into 12 clusters using the dimensionality reduction and clustering algorithms in the 10X Cell Ranger pipeline (Fig 5A, 5B and 5C ). The expression profile of 20 myeloid and lymphoid lineage markers (S100a4, S100a9, Cd8b1, Cd4, Cd79a, Ms4a1, Cybb, Mafb, Cd3g, Fcgr3, Cst3, Nme1, Itgam, Cd8a, Lig1, Ccna2, Ccr7, Il7r, Ncr1 and Nkg7) allowed us to assign biological identities to each cluster (Fig 5D) . For each lineage marker, the average expression and percent positivity within each cluster were similar across all experimental groups (S1 Fig). We identified four T cell clusters (clusters 0, 2, 4 and 7), two B cell clusters (clusters 3 and 9), three myeloid-cell clusters (clusters 6, 8, and 10), one basophil cluster (cluster 11), one neutrophil cluster (cluster 

Mycobacterium tuberculosis and SARS-CoV-2 coinfection in mice 5), and one natural killer-cell cluster (cluster 1) (Fig 5A) . The extent to which these clusters were represented among all CD45+ cells varied by group (Fig 5C and 5E ). We observed that innate clusters (i.e. NK, neutrophil, DC, MØ, CD11b+ MØ and basophils) comprised 50% of the UI lung, with T cells (42%) and B cells (8%) making up the difference (Fig 5D) . In Mtb NEG-MACoV2 POS lungs, the representation of T cell (51%) and B cell (16%) clusters was higher, as were DC (4%) and MØ (7%) clusters. Relative to UI lungs, the Mtb POS MACoV2 NEG lung was characterized by the expansion of nearly all immune clusters (CD8 T cells, 8!15%; B cells, 6!13%; CD8 memory T cells, 7!9%; DCs, 2!4%; CD4 T cells, 3!6%; CD11b+ MØ, 1!2%; activated B cells, 2!4%; MØ, 1!5%) at the expense of neutrophils (17!7%), NK cells (28!15%) and naïve T cells (24!21%). Importantly, the profile of Mtb POS MACoV2 POS lungs closely resembled that of Mtb POS MACoV2 NEG lung, with the exception of expanded B cell (17%), CD8 memory T cell (10%), DC (6%) and activated B cell (5%) clusters, again at the expense of neutrophils, NK cells and naïve T cells (Fig 5D) . Collectively, our scRNA seq data demonstrates the resistance of Mtb-infected mice to MACoV2 is associated with a lung immune environment that is largely similar to that observed in Mtb monoinfected lungs, with the exception of expanded T and B cell clusters.

Our results demonstrate that Mtb infected mice on the C57BL/6 genetic background are resistant to secondary infection with CoV2 and its pathological consequences. With regards to the mechanism of resistance, we believe the inflammatory nature of Mtb infection creates a lung environment that is inhospitable to CoV2 propagation. In the absence of Mtb, CoV2 enter cells via ACE2, propagates and triggers and inflammatory response that extends after CoV2 clearance and causes declines in lung function and death [17] . In the presence of Mtb, CoV2 entry is likely unaffected since ACE2 is abundantly expressed in the Mtb-infected lung, but the extent of CoV2 propagation is low and the immunopathological responses typically triggered in mice (i.e. weight loss, pneumonia) are muted. This is likely due to one or both of the following reasons: (1) Mtb infected lungs already contain an array of immune innate lineages which restrict CoV2, or (2) Mtb elicits an adaptive immune response that cross reacts with CoV2 antigens and offers heterologous immunity. This latter explanation is supported by recent epidemiological studies of COVID among individuals vaccinated with M. bovis BCG [18] [19] [20] , which depending on the strain has significant antigenic overlap with Mtb [21, 22] . The limitations of our study include its being performed in mice, which of course do not recapitulate all aspects of TB or COVID in humans, nor have we examined the long term impact of CoV2 on the host response to Mtb as we terminated our study fourteen days after CoV2 challenge. That said, we believe animal models of TB and COVID are ideal for studies of this nature becauseif studies of COVID in individuals with other chronic lung diseases are any guide [23, 24] -it will likely be difficult to tease apart the impact of TB on COVID outcomes in humans given that individuals with TB often have numerous other comorbidities (e.g. malnourishment, HIV) that confound interpretation. Translated to human COVID susceptibility, our results suggest that individuals infected with Mtb generate an immune response that offers a degree of protection from subsequent or secondary infection with CoV2.

We believe our study raises a number of important questions which can be answered by future research, including (but not limited to) the following:

Do our findings extend to other models of TB which better recapitulate the range of human disease? As expertly reviewed elsewhere [25] , mice are an imperfect model of TB because they do not display the spectrum of pathology observed in humans with TB. This is especially true of mice on the C57BL/6 genetic background, which are resistant to TB in the absence of any

Mycobacterium tuberculosis and SARS-CoV-2 coinfection in mice induced or genetic immunodeficiency [26] . It will be important to test if our results can be generalized to other models which do display a greater range of TB and COVID disease forms (e.g. NHP, Diversity Outbred mice) [27] [28] [29] . Related to this is the question of whether the resistance we observed varies with the stage of TB disease, as the cellular composition, cytokine milieu and protective capacity of the TB granuloma waxes and wanes over time [30] .

What is the mechanism of acute COVID disease resistance in Mtb-infected mice? Whether the expansion of B cell or CD8 T cells we observed in Mtb POS CoV2 POS mice is indicative of their having protective properties in the context of co-infection can be determined via classic immunology methods such as lineage depletions and/or adoptive transfers. So too can sera from Mtb infected animals be tested for neutralizing or protective capacity against CoV2 challenge, since there may be antibodies present to the numerous mycobacterial proteins that are homologous to CoV2 antigens [9] [10] [11] .

How is the human immune response to TB affected by COVID? As the acute crisis stage of the COVID pandemic has (hopefully) begun to move into the past with the advent of effective vaccines, scattered reports are emerging of interesting associations between COVID and Interferon-Gamma Release assay (IGRA) results. IGRAs are whole-blood tests which detect secretion of IFNγ in response to two or three synthetic, Mtb-specific peptides depending on the manufacturer (QuantiFERON-TB Gold In-Tube test: ESAT-6, CFP-10 & TB7.7; T-SPOT TB test: ESAT-6 & CFP-10), relative to a negative control antigen (nil) and a positive control antigen (the polyclonal mitogen phytohemagglutinin, PHA). A "positive IGRA" is indicative of active or prior Mtb infection; an "indeterminate IGRA" can stem from either an insufficient response to the positive control, or too high a background response to the negative control. Consistent with our present animal model study, Gupta et al observed that a cohort of 20 asymptomatic COVID patients were more likely to have a positive IGRA than 20 severely ill COVID patients [31] , suggesting those with prior TB exposure are less likely to develop symptoms following CoV2 infection. Equally interesting are elevated rates of indeterminate IGRA in hospitalized COVID patients, due to too low IFNγ levels in the positive control blood collection tubes [32, 33] . Another recent study [34] of 10 COVID patients with active TB and 11 COVID patients with latent TB shows that both groups retain their ability to respond to Mtb antigens as measured via IGRA, but (compared to 63 COVID patients with no history of TB) the blood of those with active TB (not latent TB) are less responsive to CoV2 antigens. Our animal model data would suggest this later result could be due to either the inflammatory environment limiting CoV2 replication (resulting in less viral antigens for generating an adaptive response in the first place). Alternatively since most of the T cell compartment localizes to the lung (away from the circulation) in those with active TB, due to the array of chemokines that attract both Mtb-specific and non-Mtb-specific T cells alike [35] , lower CoV2 antigen responsiveness in the blood may reflect lower T cell numbers in the blood. That hospitalized individuals with COVID are often treated with corticosteroids is an additional confounder of human TB/COVID co-infection studies.

Finally, TB and COVID are ongoing pandemics and our results should not be used to support any assertion that those with TB (or history of TB) will not get COVID, nor should they be used to support any assertion that those with TB (or history of TB) should not get vaccinated against COVID. Hospitalization and severe forms of COVID can now be prevented by several vaccines; the US Centers for Disease Control and Prevention, European Centre for Disease Prevention and Control, and World Health Organization each maintain updated lists of these vaccines on their respective websites (https://www.cdc.gov, https://www.ecdc.europa.eu, https://www.who.int). We do hope and anticipate that our results will be used to support future studies of patient populations and animal models to improve knowledge of the TB/ COVID interaction.

All animal studies were reviewed and approved by the local Institutional Animal Care and Use Committee (OSU IACUC) prior to their onset (Approval # 2018A00000076 and 2020A00000044).

All experiments involving SARS-CoV-2 followed procedures and protocols that are approved by The Ohio State University (OSU) Institutional Biosafety Committee. SARS-CoV-2, isolate USA-WA1/2020, was obtained from Biodefense and Emerging Infections Research Resources Repository (BEI Resources, Batch # 70034262). Mouse adapted SARS-CoV-2 variant strain MA10 [36] was likewise provided by BEI Resources (Cat # NR-55329). Virus was cultured, prepared and authenticated as we recently reported [37] . Namely, to establish the viral stocks used in our studies, a virus aliquot was thawed, diluted 1:10,000 in incomplete DMEM (Gibco; supplemented with 4.5 g/L D-glucose, 110 mg/L sodium pyruvate) and added to confluent VeroE6 cells (ATCC). Cells were incubated with virus for 1h (37˚C, 5% CO 2 ), after which time the media was replaced with complete DMEM (i.e. DMEM prepared as above, further supplemented with 4% heat-inactivated fetal bovine serum) and the cells were incubated for 3 days (37˚C, 5% CO 2 ) to allow virus propagation. After that period, visual inspection under light microscopy demonstrated near complete death of the infected VeroE6 cells. The supernatant was collected into 50mL conicals, centrifuged at low speed to remove cell debris and subsequently aliquoted, frozen and stored at -80˚C. These frozen aliquots served as the stock tubes for all subsequent experiments. The live virus titer of our frozen aliquots was determined via the plaque assay described below. SARS-CoV-2 stocks were authenticated using a clinically validated clinical next-generation sequencing assay [38] .

All experiments involving M. tuberculosis (Mtb) followed procedures and protocols that are approved by The Ohio State University (OSU) Institutional Biosafety Committee. The virulent Mtb strain H37Rv (Trudeau Institute, Saranac Lake, NY) was grown in Proskauer Beck medium containing 0.05% tyloxapol to mid-log phase (37˚C, 5% CO 2 ) and frozen in 1-ml aliquots at −80˚C. The live bacteria titer of our frozen aliquots was determined via plating serial dilutions on 7H11 agar media. To authenticate our Mtb stock we confirmed that the colony morphology, in vitro growth characteristics and in vivo virulence were consistent with our previous studies using the H37Rv strain [39] .

All mice were treated in accordance with OSU Institutional Animal Care and Use Committee (IACUC) guidelines and approved protocols. C57BL/6 and hemizygous K18-hACE C57BL/6J mice (strain: 2B6.Cg-Tg(K18-ACE2)2Prlmn/J) were purchased from Jackson Laboratory (Bar Harbor, ME) and housed at OSU within an AALAC-accredited facility (University Laboratory Animal Resources, ULAR).

Mice were aerosol infected with Mtb H37Rv per our previous studies using the Glas-Col inhalation system [39] . For bacterial load determinations, the lungs, spleen, and liver were aseptically removed and individually homogenized in sterile normal saline (Gentle Macs system,

Mycobacterium tuberculosis and SARS-CoV-2 coinfection in mice program "RNA" run 2X). Serial dilutions of each organ were then plated on 7H11 and colonies counted after 2-3 weeks incubation at 37˚C 5% CO 2 . Lungs from control mice were plated on post-infection Day 1 to verify the delivery of~80 Mtb CFU.

Mice that were either uninfected (UI) or previously infected with aerosol Mtb (Mtb POS ) mice were challenged with either CoV2 or MACoV2. At the time of challenge, mice were anesthetized with isoflurane, weighed and held at a semi-supine position while 50 μL of CoV2-containing PBS (2.5 × 10 4 PFU) or MACoV2 (2.5 × 10 4 PFU) was given via intranasal (i.n.) instillation. Control mice were given the same volume of sterile PBS, using the same anesthesia and i.n. instillation protocol. After i.n. instillation, each mouse was returned to its home cage, house and monitored daily for changes in weight or body condition. For viral load determinations, the lungs of challenged animals were aseptically removed and individually homogenized as described above; serial dilutions were then used in the plaque assay described below.

A modified version of the plaque assay developed by the Diamond laboratory [40] was used to determine lung viral burdens in challenged animals, the details of which we have reported [41] . Namely, one day prior to the assay start we seeded 12-well with VeroE6 cells and incubated overnight (37˚C 5% CO 2 ) such that each well was confluent by the assay start. On the day of the assay, serial dilutions of virus-containing material (e.g. lung homogenate) were prepared in cDMEM and warmed to 37˚C. Media from each well of the 12-well plate was gently removed via pipette and replaced with 500uL of each virus sample dilution, the volume pipetted down the side of the well so as not to disturb the VeroE6 monolayer. The plate was incubated for 1 hr at 37˚C 5% CO 2 . During this incubation period, a solution comprising a 1:0.7 mixture of cDMEM and 2% methylcellulose (viscosity: 4000 cP) was freshly made and warmed to 37˚C in a water bath. After the 1 hr incubation period was over, the supernatant was removed from each well and replaced with 1 mL of the pre-warmed cDMEM:methylcellulose mixture. The culture plate was then returned to the incubator and left undisturbed for 3 days. On the final day, the cDMEM:methylcellulose mixture was removed from each well, cells were fixed with 4% para-formaldehyde in PBS (20 minutes, room temperature), washed with PBS and stained with 0.05% crystal violet (in 20% methanol). After rinsing plates with distilled water, plates were dried, and plaques were counted under a light microscope.

The inferior lung lobe was removed from mice and fixed in 10% formalin. Sample processing, paraffin embedding, H&E and acid fast bacilli (AFB) staining was performed by the OSU Comparative Pathology & Mouse Phenotyping Shared Resource (CPMPSR). Immunohistochemistry (IHC) was performed using a monoclonal antibody specific to SARS-CoV-2 Nucleocapsid (clone B46F; ThermoFisher) per previously reported methods [42] . Histology slides were imaged using a Nikon Ti2 widefield microscope fitted with 4x, 10x and 60x CFI Plan Fluor objectives and a DS-Fi3 color camera. Images were processed using FIJI [43] and compiled using BioRender.com. The individual and cumulative areas of each TB granuloma in Mtb POS CoV2 NEG and Mtb POS CoV2 POS lungs were determined using our previously reported methods [44] .

CoV2 N protein levels in lung homogenates were determined using a commercially available ELISA kit (ADS Biotec), as were protein levels of the cytokines IL1β, IL6 and IFNγ (Biolegend). ELISA kits were used per manufacturer protocols.

Lung RNA was extracted from the superior lung lobe using the RNeasy Mini Kit method (Qiagen) and reverse transcribed using the SuperScript VILO cDNA Synthesis Kit method (Ther-moFisher). Quantitative real time PCR (qRT-PCR) was performed on a C1000 Touch Thermocycler (Bio-Rad) using SYBR Select Master Mix (Applied Biosystems) per manufacturer protocols. The primer sequences used to amplify cDNA for genes of interest were previously published [45, 46] . Each biological replicate was performed in technical duplicate and data were analyzed using the ΔΔCt method.

To purify live CD45+ cells for single cell RNA sequencing, lungs from uninfected, Mtb-or MACoV2-monoinfected and Mtb/MACoV2 coinfected mice were removed and treated in an identical manner. Lungs were first digested in a DNase/collagenase mixture [47] ; dead cells from the resulting slurry were then removed via negative magnetic selection using the Dead Cell Removal kit method (Miltenyi). The live cells were then mixed with CD45 microbeads (Miltenyi) and used for positive magnetic selection of live CD45+ cells. Trypan blue staining was used to confirm cell viability. Cells were the prepared for single cell partitioning via a 10X Genomics Chromium Controller using manufacturer provided protocols (10x Genomics Document Number CG000136). 1 x 10 4 cells per experimental group were loaded onto the Controller and partitioned, as carried out by the OSU Genomics Shared Resource core.

scRNA-seq libraries were prepared and analyzed using the 10X Genomics and Illumina platforms, respectively, per previously reported methods [48] .

All experiments were performed using randomly assigned mice without investigator blinding. All data points and p values reflect biological replicates from at least two independent experiments per figure (4 mice per group per timepoint). Statistical analysis was performed using GraphPad Prism. Unpaired, two-tailed Student t tests and one-way ANOVA tests with post hoc Tukey-Kramer corrections were used to assess statistical significance. Graphs were likewise generated in GraphPad Prism. The only exception to this were the t-distributed stochastic neighbor embedding (t-SNE), annotation and graphing associated with our scRNA analysis, which was performed with Cell Ranger and RStudio. 

Mycobacterium tuberculosis and SARS-CoV-2 coinfection in mice

Relationship of SARS-CoV-2-specific CD4 response to COVID-19 severity and impact of HIV-1 and tuberculosis coinfection

Implications of COVID-19 in high burden countries for HIV/TB: A systematic review of evidence

Pathology of TB/COVID-19 Co-Infection: The phantom menace

Changes in Mycobacterium tuberculosis-Specific Immunity With Influenza co-infection at Time of TB Diagnosis

The convergent epidemiology of tuberculosis and human cytomegalovirus infection

Influenza virus infection is associated with increased risk of death amongst patients hospitalized with confirmed pulmonary tuberculosis in South Africa

Influenza A virus impairs control of Mycobacterium tuberculosis coinfection through a type I interferon receptor-dependent pathway

Association of the past epidemic of Mycobacterium tuberculosis with mortality and incidence of COVID-19

BCG Vaccine Derived Peptides Induce SARS-CoV-2 T Cell Cross-Reactivity

Antigenic sites in SARS-CoV-2 spike RBD show molecular similarity with pathogenic antigenic determinants and harbors peptides for vaccine development

Strong homology between SARS-CoV-2 envelope protein and a Mycobacterium sp. antigen allows rapid diagnosis of Mycobacterial infections and may provide specific anti-SARS-CoV-2 immunity via the BCG vaccine

SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function

A mouseadapted model of SARS-CoV-2 to test COVID-19 countermeasures

Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2

Progression of chronic pulmonary tuberculosis in mice aerogenically infected with virulent Mycobacterium tuberculosis

SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues

Characteristics of SARS-CoV-2 and COVID-19

BCG vaccine protection from severe coronavirus disease 2019 (COVID-19)

Regional BCG vaccination policy in former East-and West Germany may impact on both severity of SARS-CoV-2 and incidence of childhood leukemia

BCG-induced trained immunity: can it offer protection against COVID-19?

In-vivo expressed Mycobacterium tuberculosis antigens recognised in three mouse strains after infection and BCG vaccination

Genome sequencing and analysis of BCG vaccine strains

Impact of smoking, COPD and comorbidities on the mortality of COVID-19 patients

Outcomes of SARS-CoV-2 infection in patients with pulmonary sarcoidosis: A multicenter retrospective research network study

Animal models of tuberculosis

Genetic control of susceptibility to infection with Mycobacterium tuberculosis in mice

The End of the Binary Era: Revisiting the Spectrum of Tuberculosis

Medical imaging of pulmonary disease in SARS-CoV-2-exposed non-human primates

CXCL1: A new diagnostic biomarker for human tuberculosis discovered using Diversity Outbred mice

Tuberculosis in the elderly: Why inflammation matters

Positive QuantiFERON test and the severity of COVID-19 disease: A prospective study

Indeterminate QuantiFERON Gold Plus Results Reveal Deficient Interferon Gamma Responses in Severely Ill COVID-19 Patients

Clinical Significance of Indeterminate QuantiFERON-TB Gold Plus Assay Results in Hospitalized

Patients with Severe Hyperinflammatory Syndrome

Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2

A limited antigen-specific cellular response is sufficient for the early control of Mycobacterium tuberculosis in the lung but is insufficient for long-term survival

A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice

Syrian hamsters as a model of lung injury with SARS-CoV-2 infection: pathologic, physiologic and detailed molecular profiling

Mutation-Specific SARS-CoV-2 PCR Screen: Rapid and Accurate Detection of Variants of Concern and the Identification of a Newly Emerging Variant with Spike L452R Mutation

Early control of Mycobacterium tuberculosis infection requires il12rb1 expression by rag1-dependent lineages

Growth, detection, quantification, and inactivation of SARS-CoV-2

SARS-CoV-2 disinfection in aqueous solution by UV222 from a krypton chlorine excilamp

VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats

Fiji: an open-source platform for biological-image analysis

Dietary Vitamin D3 Suppresses Pulmonary Immunopathology Associated with Late-Stage Tuberculosis in C3HeB/FeJ Mice

Expression of SARS-CoV-2 receptor ACE2 and TMPRSS2 in human primary conjunctival and pterygium cell lines and in mouse cornea

Identification of an Increased Alveolar Macrophage Subpopulation in Old Mice That Displays Unique Inflammatory Characteristics and Is Permissive to Mycobacterium tuberculosis Infection

Standardized preparation of single-cell suspensions from mouse lung tissue using the gentleMACS Dissociator

Targeting PIM1-Mediated Metabolism in Myeloid Suppressor Cells to Treat Cancer

We would like to acknowledge the laboratories of Jianrong Li (OSU), Mark Peeples (OSU & Nationwide Children's Hospital) and Jacob Yount (OSU) who grew and provided the MACoV2 used in our studies, as well as BSL3 Director Luanne Hall-Stoodley and BSL3 Research Assistant Abigail Mayer for maintaining the facilities needed for our studies.

Mycobacterium tuberculosis and SARS-CoV-2 coinfection in mice